HEPATOLOGY RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-07-10 YJJJJJ

中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。
审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。

61 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-08-09 148bf9cam55暂无昵称

偏重的研究方向：肝癌
经验分享：这个杂志送外审了状态也还是Under Review吗

108 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-06-07 ms7000000962482370

审稿速度:2.0
经验分享：不是审稿周期蛮短的吗，怎么一直没消息

55 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-05-06 ms1000000867109818

请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！

66 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-07-13 xujianbo1987 来自江苏省

请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊

45 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-04-27 YJJJJJ

审稿速度:1.0
经验分享：审稿非常快，从投稿到接收用时一个月。

65 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2020-06-03 1861eaa8b6m

审稿速度:1.0 | 投稿命中率:50.0
经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧

136 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2019-01-16 ninininininnini

“EO：XXXXXXX
under review”是什么意思，是编辑部在处理稿件格式，还是外审中

407 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-28 小动量

引言三段式指的是什么?

55 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。 审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向：肝癌 经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0 经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0 经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 msSSSSSD

引言一般是三段式么？

74 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务